KR101197325B1 - 대식 세포 엘라스타아제의 억제제인 5-［3-(4-벤질옥시페닐티오)-퓨르-2-일］-이미다졸리딘-2,4-디온 및 유사 화합물 - Google Patents

대식 세포 엘라스타아제의 억제제인 5-［3-(4-벤질옥시페닐티오)-퓨르-2-일］-이미다졸리딘-2,4-디온 및 유사 화합물 Download PDF

Info

Publication number
KR101197325B1
KR101197325B1 KR1020077006294A KR20077006294A KR101197325B1 KR 101197325 B1 KR101197325 B1 KR 101197325B1 KR 1020077006294 A KR1020077006294 A KR 1020077006294A KR 20077006294 A KR20077006294 A KR 20077006294A KR 101197325 B1 KR101197325 B1 KR 101197325B1
Authority
KR
South Korea
Prior art keywords
mmp
inhibitors
dione
fur
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077006294A
Other languages
English (en)
Korean (ko)
Other versions
KR20070045330A (ko
Inventor
푸드 양
Original Assignee
큐피에스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 큐피에스 엘엘씨 filed Critical 큐피에스 엘엘씨
Publication of KR20070045330A publication Critical patent/KR20070045330A/ko
Application granted granted Critical
Publication of KR101197325B1 publication Critical patent/KR101197325B1/ko
Assigned to 포시 파마슈티컬스 컴퍼니 리미티드 reassignment 포시 파마슈티컬스 컴퍼니 리미티드 권리의 전부이전등록 Assignors: 큐피에스 엘엘씨
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077006294A 2004-08-19 2005-08-17 대식 세포 엘라스타아제의 억제제인 5-［3-(4-벤질옥시페닐티오)-퓨르-2-일］-이미다졸리딘-2,4-디온 및 유사 화합물 Expired - Fee Related KR101197325B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60273604P 2004-08-19 2004-08-19
US60/602,736 2004-08-19
PCT/US2005/029259 WO2006023562A2 (en) 2004-08-19 2005-08-17 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase

Publications (2)

Publication Number Publication Date
KR20070045330A KR20070045330A (ko) 2007-05-02
KR101197325B1 true KR101197325B1 (ko) 2012-11-05

Family

ID=35968136

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077006294A Expired - Fee Related KR101197325B1 (ko) 2004-08-19 2005-08-17 대식 세포 엘라스타아제의 억제제인 5-［3-(4-벤질옥시페닐티오)-퓨르-2-일］-이미다졸리딘-2,4-디온 및 유사 화합물

Country Status (16)

Country Link
US (1) US7179831B2 (https=)
EP (1) EP1789036B1 (https=)
JP (1) JP5042833B2 (https=)
KR (1) KR101197325B1 (https=)
CN (1) CN101014338B (https=)
AT (1) ATE508744T1 (https=)
AU (1) AU2005277432B2 (https=)
BR (1) BRPI0514470B8 (https=)
CA (1) CA2577430C (https=)
DK (1) DK1789036T3 (https=)
ES (1) ES2364068T3 (https=)
MX (1) MX2007001940A (https=)
NZ (1) NZ553258A (https=)
RU (1) RU2391339C2 (https=)
SI (1) SI1789036T1 (https=)
WO (1) WO2006023562A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051260A1 (en) * 2006-01-13 2008-05-02 Battelle Memorial Institute Methods for assessing copd-retlated diseases
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
DK3503885T3 (da) * 2016-08-19 2022-06-20 Foresee Pharmaceuticals Co Ltd Farmaceutisk præparat og fremgangsmåder til anvendelse heraf
US10532102B2 (en) * 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
KR102409533B1 (ko) * 2016-09-23 2022-06-15 가껭세이야꾸가부시기가이샤 (r)-5-(3,4-디플루오로페닐)-5-[(3-메틸-2-옥소피리딘-1(2h)-일)메틸]이미다졸리딘-2,4-디온의 제조 방법 및 그 제조를 위한 중간체
KR102861502B1 (ko) * 2018-05-15 2025-09-18 포시 파마슈티컬스 유에스에이 인코포레이티드 기질 금속단백분해효소 (mmp) 억제제 및 이의 사용 방법
CN115667227B (zh) 2019-11-14 2024-11-01 逸达生物科技股份有限公司 基质金属蛋白酶(mmp)抑制剂及其使用方法
EP4351566A4 (en) * 2021-06-08 2025-04-23 Foresee Pharmaceuticals USA, Inc. SAFE ADMINISTRATION OF MMP-12 INHIBITOR
RU2766551C1 (ru) * 2021-07-19 2022-03-15 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) 5-(4-хлорфенил)-3-((4-хлорфенил)амино)-5-(фенилтио)фуран-2(5н)-он, обладающий противомикробной активностью

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074752A1 (en) 2001-03-15 2002-09-26 Astrazeneca Ab Metalloproteinase inhibitors
WO2004020415A1 (en) 2002-08-27 2004-03-11 Astrazeneca Ab 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12.
US20040067996A1 (en) 2002-10-04 2004-04-08 James Sheppeck Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352976B1 (en) * 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
AU1817700A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
RU2150469C1 (ru) * 1999-06-01 2000-06-10 Уфимский государственный нефтяной технический университет Способ получения 2-(фурил-2)-1,3-имидазолидинов
AU4882101A (en) 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
CA2447475A1 (en) 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
EP1394159A1 (fr) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074752A1 (en) 2001-03-15 2002-09-26 Astrazeneca Ab Metalloproteinase inhibitors
WO2004020415A1 (en) 2002-08-27 2004-03-11 Astrazeneca Ab 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12.
US20040067996A1 (en) 2002-10-04 2004-04-08 James Sheppeck Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)

Also Published As

Publication number Publication date
JP2008510701A (ja) 2008-04-10
CA2577430C (en) 2010-12-07
EP1789036A2 (en) 2007-05-30
EP1789036A4 (en) 2008-08-27
AU2005277432B2 (en) 2011-11-24
DK1789036T3 (da) 2011-06-27
RU2007105822A (ru) 2008-09-27
WO2006023562B1 (en) 2006-06-22
JP5042833B2 (ja) 2012-10-03
CN101014338B (zh) 2010-06-16
RU2391339C2 (ru) 2010-06-10
KR20070045330A (ko) 2007-05-02
SI1789036T1 (sl) 2011-09-30
WO2006023562A2 (en) 2006-03-02
ATE508744T1 (de) 2011-05-15
AU2005277432A1 (en) 2006-03-02
CA2577430A1 (en) 2006-03-02
BRPI0514470B8 (pt) 2021-07-20
HK1107774A1 (en) 2008-04-18
US20060041000A1 (en) 2006-02-23
EP1789036B1 (en) 2011-05-11
BRPI0514470B1 (pt) 2021-01-05
CN101014338A (zh) 2007-08-08
US7179831B2 (en) 2007-02-20
BRPI0514470A (pt) 2008-06-10
ES2364068T3 (es) 2011-08-24
MX2007001940A (es) 2007-07-24
NZ553258A (en) 2011-02-25
WO2006023562A3 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
JP3801653B2 (ja) ヒドラジン誘導体
Yadav et al. Chiral ionic liquid-catalyzed Biginelli reaction: stereoselective synthesis of polyfunctionalized perhydropyrimidines
CN114573575A (zh) 一类含氧五元杂环化合物、合成方法、药物组合物及用途
UA77667C2 (en) Metalloproteinase inhibitors, pharmaceutical composition and use thereof
SK10912003A3 (sk) Metaloproteinázové inhibítory
HUT77668A (hu) Vírusellenes hatású 5,6-dihidropiron-származékok és hatóanyagként azokat tartalmazó gyógyszerkészítmények
KR101197325B1 (ko) 대식 세포 엘라스타아제의 억제제인 5-［3-(4-벤질옥시페닐티오)-퓨르-2-일］-이미다졸리딘-2,4-디온 및 유사 화합물
EP1150996B1 (en) New amidinobenzylamine derivatives and their use as thrombin inhibitors
WO2014017516A1 (ja) ４－［５－（ピリジン－４－イル）－１ｈ－１，２，４－トリアゾール－３－イル］ピリジン－２－カルボニトリルの製造方法および中間体
HUT75225A (en) 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
EP1944290A1 (en) Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity
CA3256685A1 (en) AZOLO COMPOUNDS FOR THE TREATMENT OF FIBROTIC DISEASES
EP1615629B1 (en) Peptide deformylase inhibitors
Bakulina et al. Mixed carboxylic–sulfonic anhydride in reaction with imines: A straightforward route to water-soluble β-lactams via a Staudinger-type reaction
Shutalev et al. Utilization of the amidoalkylation reaction in the synthesis of hydrogenated pyrimidine-2-thiones
DE60113406T2 (de) N-substituierte peptidylnitrile als cystein-cathepsin-inhibitoren
CN1023645C (zh) 外消旋螺海因的新拆分法
HK1107774B (en) 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2, 4-dione and analogues useful as inhibitors of macrophage elastase
KR100441361B1 (ko) 프로테아제억제제및항바이러스제로서의5,6-디히드로피론유도체
JP3201194B2 (ja) アミド誘導体
Balsamo et al. New β-lactam monocyclic inhibitors of human elastases: Synthesis and anti-elastase properties of 1-carbamoyl-4-methyleneaminoxyazetidinone derivatives
JPS634831B2 (https=)
HUP9903675A2 (hu) Új acetamid-származékok és proteáz inhibitorok
KR20050108682A (ko) 라시디핀의 개선된 합성방법
JP2002161036A (ja) ホスホジエステラーゼ阻害剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20151002

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160929

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20201030

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20201030